Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15066588 | 0.72 | KDM4E (0.42) | KDM4E | |
| Acetone SCHEMBL2190153 | 0.64 | KDM4E (0.35) | KDM4E | |
| Acetone SCHEMBL629229 | 0.64 | KDM4E (0.40) | KDM4E | |
| SCHEMBL15066590 | 0.64 | KDM4E (0.50) | KDM4E | |
| Acetone SCHEMBL17273898 | 0.64 | KDM4E (0.35) | KDM4E | |
| Acetone SCHEMBL12813654 | 0.64 | KDM4E (0.39) | KDM4E | |
| SCHEMBL1256560 | 0.62 | KDM4E (0.39) | KDM4E | |
| SCHEMBL16327606 | 0.58 | L3MBTL1 (0.47) | KDM4E | |
| SCHEMBL2264845 | 0.57 | MAPK1 (0.37) | KDM4E | |
| SCHEMBL7413307 | 0.55 | BRD4 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060153839-A1 | Production of bispecific molecules using polyethylene glycol linkers | ELUSYS THERAPEUTICS, INC. (US) | 2006-07-13 | — | — | US | disclosed |
| EP-1539811-A4 | PRODUCTION OF BISPECIFIC MOLECULES USING POLYETHYLENE GLYCOL LINKERS | ELUSYS THERAPEUTICS INC (US) | 2006-05-24 | — | — | EP | disclosed |
| EP-1539811-A2 | PRODUCTION OF BISPECIFIC MOLECULES USING POLYETHYLENE GLYCOL LINKERS | Elusys Therapeutics, Inc. (US) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004024889-A2 | PRODUCTION OF BISPECIFIC MOLECULES USING POLYETHYLENE GLYCOL LINKERS | ELUSYS THERAPEUTICS, INC. (US) | 2004-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060153839-A1 | Production of bispecific molecules using polyethylene glycol linkers | TNFSF11, TNFSF10, CLTA | KDM4E 3193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.